On Tuesday September 27th 2022, psychedelics company MindMed (MMED.NE) announced the pricing of a public offering of common shares and warrants. An offering that the market saw as highly…
MindMEd
Some positive action on psychedelic stocks in the last few days. As a technical analyst, there are good signs indicating a reversal is occurring. The downtrend is over, and…
Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
The psychedelics sector is looking ready for a reversal. We are just waiting for the breakout confirmation. Earlier this week, we discussed how the bottom is in for cannabis…
Not So Generalized Disorder “Anxiety is a part of normal life.” Or so I was told. Whether I was simply leaving my apartment to get food or speaking during…
Just micro-dosed a few minutes ago to stay on theme for this 2022 technical outlook. Psychedelics. 2021 was the year I was introduced to the benefits of psychedelics. Mind…
$901.372M Market Capitalization Mind Medicine Inc. (MNMD.Q) today announced the initiation of a Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely sure what an ETF…
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…